Charles River Laboratories International, Inc., incorporated on February 3, 1994, is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support its clients' manufacturing activities.
Research Models and Services
The RMS segment consists of the production and sale of research models. Through its RMS segment, the Company supplies research models to the drug development industry. A portion of Research Models business consists of the commercial production and sale of research models, principally purpose-bred rats and mice for use by researchers. The Company provides its rodent models to various clients across the world, including pharmaceutical companies, a range of biotechnology companies, and various government agencies, hospitals, and academic institutions. As of December 31, 2016, the Company had its production facilities located in eight countries. The Company's research models include standard stocks and strains and disease models, such as those with immune systems, which are in demand as early-stage research tools. The Company's research models are bred and maintained in a range of controlled environments, which are designed to ensure that the models are free of specific viral and bacterial agents and other contaminants that can disrupt research operations and distort research results.
The Company's research models include outbred, which are purposefully bred for heterogeneity; inbred, which are bred to be homogeneous; spontaneous mutant, whose genotype results in a naturally occurring genetic mutation (such as immune deficiency); hybrid, which are the offspring of two various inbred parents, and other genetically modified research models, such as knock-out models with one or more disabled genes and transgenic models. Certain of its research models are disease-specific rodent models used to research treatments for diseases, such as diabetes, obesity, cardiovascular and kidney disease. The Company is also a provider of purpose bred, specific-pathogen-free (SPF) research models to the biomedical research community. RMS also offers a range of services designed to support its clients' use of research models in research and screening non-clinical drug candidates. The Company's services include those, which are related to the maintenance and monitoring of research models, and managing research operations for government entities, academic organizations, and commercial clients. The Company has three service offerings in research models services: Genetically Engineered Models and Services, Insourcing Solutions, and Research Animal Diagnostic Services.
Discovery and Safety Assessment
The DSA segment offers discovery and safety assessment services, both regulated and non-regulated, in, which the Company includes both in vitro and in vivo studies, supporting laboratory services, and strategic non-clinical consulting and program management to support product development. The Company offers a spectrum of discovery services from identification of a druggable target, followed by screening and medical chemistry, through delivery of non-clinical drug and therapeutic candidates ready for safety assessment. The Company's Early Discovery and In Vivo Discovery businesses are integrated into a single business line that is Discovery Services to streamline the support that the Company can provide for clients' integrated drug discovery programs. The Company supports a range of therapeutic areas, including oncology, central nervous system, bone and musculoskeletal, inflammation, metabolic diseases, respiratory and fibrotic diseases, cardiovascular, gastrointestinal, genito-urinary, anti-infectives, and ophthalmology. The Company also provides expertise in the area of rare and orphan diseases, which are typically diseases of unmet medical need in smaller patient populations, such as myotonic dystrophy, cystic fibrosis and Huntington's disease.
The Company provides integrated drug discovery services, with a focus on in vitro biology capabilities and medicinal chemistry. The Company's suite of service offerings allows the Company to support its clients at the earliest stages of their research, and to stay with them through the early-stage process. The Company also offers ion channel testing and in vitro cardiac safety assessment services, for both discovery and non-clinical purposes. In addition, the Company offers custom in vivo and in vitro genome editing. These services extend from the early discovery screening process through to in vitro GLP safety assessment testing. In vivo activities extend from 4 to 6 years in pharmaceutical research and development timelines. The Company offers research and development expertise, capabilities, and services globally to its clients' drug discovery pipelines from generation to candidate selection and on occasion, complete in vivo studies in support of clinical efforts or post-marketing work. In addition, the Company provides in vitro and in vivo assays in support of candidate selection activities.
The Company offers a range of safety assessment studies required for regulatory submission on a global basis. The Company's safety assessment studies include Bioanalysis, Drug Metabolism and Pharmacokinetics; Safety Pharmacology; Pathology Services, and Toxicology. The Company's toxicology services feature include services in specialty areas, such as ocular, bone, juvenile/neonatal, immune-toxicology, photobiology, inhalation, and dermal testing; expertise in environmental toxicology (aquatic and terrestrial) and regulatory submissions required for chemical registration, and a range offering of in vitro and in vivo capabilities and study types designed to identify possible safety risks for potential therapeutics, industrial chemicals, and agrochemicals as they transition from discovery into regulated drug development, toxicology, and human clinical testing, or as they are submitted for regulatory registration. In addition to all standard anatomic and clinical pathology techniques, the Company provides specialized evaluations, such as cytology, platelet function, assay development, immunohistochemistry, in situ blood hybridization electron microscopy, tissue morphometry, and stereology services.
Manufacturing Support
The Company's microbial solutions business provides in vitro methods for control testing of sterile and non-sterile biopharmaceutical and consumer products. The Company's business provided lot release testing of medical devices and injectable drugs for endotoxin contamination. The Company's Celsis business provides microbial detection systems for control testing in the pharmaceutical and consumer products industries. The Company's Accugenix business provides microbial identification and genetic sequencing services for manufacturing in the biopharmaceutical, medical device, nutraceutical, and consumer care industries. Endotoxin testing is an in vitro process, which uses a processed extract from the raw materials of the horseshoe crab, known as limulus amebocyte lysate (LAL). The Company's Microbial Solutions business produces and distributes a portfolio of endotoxin testing, microbial detection and identification kits, reagents, software, accessories, instruments, and associated microbial control laboratory services to a range of companies manufacturing and releasing products from the pharmaceutical, biotechnology, consumer products, and dairy industries across the world. The Company provides endotoxin testing products and services, which are used for control testing of injectable drugs and medical devices, their components, and the processes by, which they are manufactured.
The Company's Celsis' systems are principally used for product-release testing to help ensure the manufacture of pharmaceutical, pharmaceutical, and consumer products. The Advance II, Accel and Innovate systems for non-sterile applications complement its PTS-Micro, a bacterial (bioburden) detection system for sterile biopharmaceutical applications. The Company performs specialized testing of biologics outsourced by global pharmaceutical and biotechnology companies. The Company's laboratories in the United States, Germany, Scotland, Ireland, and France provide molecular biology, virology, bioanalysis, immunochemistry, microbiology and related services. The Company is engaged in supplying of SPF fertile chicken eggs and chickens. SPF chicken embryos are used by animal health companies as self-contained bioreactors for the manufacture of live viruses. These viruses are used as a raw material primarily in poultry, as well as human and veterinary vaccine applications. The production of SPF eggs is performed under biosecure conditions, similar in many ways to its research model production. The Company has global presence, with various SPF egg production facilities in the United States, and contracted production capabilities in Hungary. The Company also operates a specialized avian laboratory in the United States, which provides control testing of the SPF flocks, offers testing services to vaccine companies and commercial poultry operations, and manufactures poultry diagnostics and bulk antigens for poultry vaccines
251 Ballardvale St
The company trades on NYSE exchange. The company headquarter is located in Massachusetts, MA. The company was established in the 1947.| Ticker | CRL |
| Long Name | Charles River Laboratories International, Inc. |
| Short Name | Charles River Laboratories International |